All In Biotech

Drug Trial Radar · NCT07412080

EDP167 in Healthy Volunteers and Subjects With Mild Dyslipidemia

A Dose-escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of Single Dose of EDP167 Injection in Healthy Volunteers and Subjects With Mild Dyslipidemia

Last checked: Nov 19, 2026Latest source record: Feb 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Jul 1, 2025

Primary completion

Dec 12, 2025

Study completion Dec 12, 2025

Sponsor

Lead sponsor
Eddingpharm (Zhuhai) Co., Ltd.Industry
Sponsor type
Industry
First posted
Feb 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

EDP167 is a double-stranded small interfering RNA (siRNA) drug targeting ANGPTL3, which may bring benefits for patients with dyslipidemia conditions. This is the first in human study of EDP167 in health volunteers and subjects with mild dyslipidemia to evaluate the safety and PK/PD profiles of EDP167.

Conditions

  • Healthy Adult Male and Female Volunteers
  • Mild Dyslipidemia

Interventions

  • EDP167Drug

    EDP167 sc injection

  • PlaceboDrug

    Sterile normal saline (0.9% NaCl) sc injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety and tolerability of a single subcutaneous injection of EDP167 in adult subjects.Time frame: Up to 85 days post-dose

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Guangdong Provincial People's Hospital

    Guangzhou, China

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.